Tuberculosis infections during the COVID-19 pandemic: Comparing USA and global tuberculosis in 2019 and 2020
Background:
Tuberculosis (TB) was the worldwide leading cause of mortality from a single infectious agent before the coronavirus disease 2019 (COVID-19) pandemic. The incidence of TB infections has continually declined since 2000, but the COVID-19 pandemic has reversed this trend. In 2020, global health officials reported a 21% drop in documented cases relative to TB cases in 2019. Although previous studies evaluated the impact of the COVID-19 pandemic on global TB cases, we are not aware of reports that compared U.S. and global TB cases during the COVID-19 pandemic.
Objective:
To analyze prepandemic and pandemic volumes of TB cases within the United States and compare findings with global TB volumes.
Methods:
This descriptive study used data from the Centers for Disease Control and Prevention to compare reported TB cases in the United States in 2019 and 2020. TB cases from the United States were compared with data about global TB cases.
Results:
The COVID-19 pandemic was associated with decreased TB testing and cases in the United States. The five states with the highest number of TB cases remained the same in 2019 and 2020, and included California, Texas, New York, Florida, and New Jersey. In these states, TB predominantly occurred in non‐U.S.-born residents and most patients solely presented with pulmonary manifestations. In the United States, the most substantial risk factor for TB was diabetes mellitus.
Conclusion:
The COVID-19 pandemic decreased access to TB services and discouraged patients from seeking TB care, which inadvertently disrupted international and U.S. TB surveillance systems. Given the decline in documented TB cases, leaders may need to anticipate an increase in TB cases and begin to aggressively reallocate resources to improve TB detection and care to mitigate the recent changes.
Tuberculosis (TB) was the worldwide leading cause of mortality from a single infectious agent before the coronavirus disease 2019 (COVID-19) pandemic. The incidence of TB infections has continually declined since 2000, but the COVID-19 pandemic has reversed this trend. In 2020, global health officials reported a 21% drop in documented cases relative to TB cases in 2019. Although previous studies evaluated the impact of the COVID-19 pandemic on global TB cases, we are not aware of reports that compared U.S. and global TB cases during the COVID-19 pandemic.
Objective:
To analyze prepandemic and pandemic volumes of TB cases within the United States and compare findings with global TB volumes.
Methods:
This descriptive study used data from the Centers for Disease Control and Prevention to compare reported TB cases in the United States in 2019 and 2020. TB cases from the United States were compared with data about global TB cases.
Results:
The COVID-19 pandemic was associated with decreased TB testing and cases in the United States. The five states with the highest number of TB cases remained the same in 2019 and 2020, and included California, Texas, New York, Florida, and New Jersey. In these states, TB predominantly occurred in non‐U.S.-born residents and most patients solely presented with pulmonary manifestations. In the United States, the most substantial risk factor for TB was diabetes mellitus.
Conclusion:
The COVID-19 pandemic decreased access to TB services and discouraged patients from seeking TB care, which inadvertently disrupted international and U.S. TB surveillance systems. Given the decline in documented TB cases, leaders may need to anticipate an increase in TB cases and begin to aggressively reallocate resources to improve TB detection and care to mitigate the recent changes.
Keywords: Covid-19 pandemic; TB; Tuberculosis
Document Type: Research Article
Affiliations: 1: From the Internal Medicine Residency Program, Florida Atlantic University, Boca Raton, Florida 2: Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, and 3: Integrated Medical Science, Florida Atlantic University, Boca Raton, Florida
Publication date: 01 December 2022
- The Journal of Precision Respiratory Medicine (JPRM) is a peer reviewed publication dedicated to distributing timely information regarding cutting edge advancements in the knowledge and practice of respiratory medicine. Its primary readership extends to all medical providers with an interest in respiratory diseases.
The incorporation of the term, 'precision medicine' in its title serves to direct the journal's focus on this revolutionary approach to disease prevention and treatment that takes into account the individual differences which result from the interplay of lifestyle, environment and human biology/genetics.
JPRM seeks to publish articles characterized by both a predominant clinical focus and by having the potential to directly impact the quality of patient care. JPRM welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Pulmonary Conference (EPC) JPRM will publish content from EPC poster sessions as well as review articles derived from EPC lectures.
Click on the fast track tab below to access new pre-publication articles.
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content